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Abstract Post-translational modification of proteins by deamidation or transamidation by
tissue transglutaminase (tTG) has been suggested as a possible mechanism for the development
of autoimmunity. Sequence analysis of protein kinase C delta (PKCδ) identified an amino acid
motif that suggested the possibility that PKCδ was a glutamine substrate of tTG and MALDI-TOF
analysis of synthesised peptides from PKCδ proved that this was the case. Polymerisation
experiments using recombinant tTG and biotinylated hexapeptide substrate incorporation assays
demonstrated that PKCδ is a substrate for tTG-mediated transamidation. Elevated levels of
anti-PKCδ antibodies were detected in sera from patients with coeliac disease (p b 0.0001) but
not from patients with other autoimmune disorders. These data suggest that a subset of patients
with coeliac disease produce autoantibodies against PKCδ and that this response may stem from
a tTG–PKCδ substrate interaction.
© 2013 Elsevier Inc. All rights reserved.

1. Introduction
Coeliac disease is characterised by an inappropriate immune
response to storage proteins in certain cereal cultivars.
These prolamin proteins cause intestinal inflammation which
is associated with gastrointestinal complaints as well as
nutritional deficiencies associated with reduced absorptive
⁎ Corresponding author. Fax: + 353 1 402 4995.
E-mail address: greg.byrne@dit.ie (G. Byrne).

surface in the small intestine [1]. The disorder has a broad
spectrum of severity with some individuals having asymptomatic disease, others having fulminant responses to
ingestion of cereals such as wheat, barley and rye. The
best-characterised and most immunogenic prolamins for
coeliac patients are gliadin and glutenin derived from wheat
gluten [2].
The immune response against prolamins results in the
activation of cereal-specific T cells that are of a Th1
cytokine profile and produce interferon gamma [3]. Inflammation in the small intestine leads to villous atrophy and
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crypt hyperplasia. Coeliac disease is also associated with
humoral immune responses with antibodies produced against
gluten and the autoantigen, tissue transglutaminase (tTG).
The main reaction catalysed by tTG is the introduction of
covalent ε-(c-glutaminyl)lysine cross-links between a glutamine donor protein and a lysine donor protein [4]. In the
absence of a suitable lysine donor and in the presence of
water, tTG can deamidate its target glutamine, giving rise to a
glutamic acid residue. This enzyme plays an important role in
the disease through the site-specific deamidation of glutamine residues in the prolamin peptides. The tTG-mediated
deamidation results in negatively charged residues at important anchor positions for binding to HLA-DQ2, the coeliac
disease-associated MHC class II molecule. The increased
binding of gliadin peptides to DQ2 results in more potent T
cell responses to gliadin peptides [5].
The mechanisms by which tTG becomes an autoantigen
are not well understood but the hapten carrier complex
model as proposed by Ludwig Sollid suggests that covalent
attachment of gluten peptides to tTG facilitates their
uptake by tTG-specific B cells which receive help from
gluten-specific T cells. However, some research has demonstrated the presence of tTG-reactive T cells in patients with
coeliac disease which could drive the autoantibody response
[6]. The recent development of highly sensitive and specific
neoepitope assays where the antigen is a complex of tTG and
deamidated gliadin supports this notion that the gliadin–tTG
interaction drives the initial autoimmune response in coeliac
disease [7,8]. The detection of IgA class anti-tTG antibodies is a
highly sensitive and specific marker of coeliac disease. Anti-tTG
antibodies are detected by ELISA and the endomysial antibody
(EMA) assay, which is an indirect immunofluorescence-based
assay using monkey oesophagus. Other investigators have also
reported the presence of further auto-antibodies in coeliac sera
including antibodies to cytoskeletal actin filaments [9–11], to
epithelial cells [12], desmin [13], calreticulin [14] and
unidentified antigens [15,16]. Intriguingly, actin has been
shown to act as a substrate of tTG [17], suggesting the
possibility that a tTG-actin interaction leads to epitope
spreading from tTG to actin. Smooth muscle autoantibodies
(including those against actin) have been associated with the
observation of an “atypical” endomysial pattern, obscuring the
traditional fishnet pattern [18].

Protein kinase C delta (PKCδ) is one of 9 isoforms of the
protein kinase C enzyme family which are phospholipiddependant serine/threonine kinases that control a variety of
cellular mechanisms including proliferation, differentiation and
cell death [19]. Sequence analysis of PKCδ using the established
algorithm [5] for tTG substrate identification identified a short
span ( 541MLIGQSPFH 549) within the catalytic domain of PKCδ,
which includes the consensus tTG glutamine substrate motif
QXP where X is any amino acid (Fig. 1).
In this study, we have investigated the possibility that PKCδ
is a substrate for tTG and whether this enzyme-substrate
interaction gives rise to a humoral anti-PKCδ response in
patients with coeliac disease.

2. Materials and methods
2.1. Deamidation/transamidation reactions
The peptides MLIGQSPFH (from PKCδ), ALPTAQVPTDP (from
rat small heat shock protein 20) and PFPQPQLPYPR (from the
DQ2-α-I epitope from α-gliadin) were synthesised in the Royal
College of Surgeons in Ireland. The glutamine residues in bold
represent the target for deamidation/transamidation by tTG.
Fifty micromolar concentrations of each peptide was
incubated in reaction buffer (100 mM Tris–HCl, pH 7.2) with
0.1 μg/μl of recombinant human tTG, either in the presence
(for transamidation) and absence (for deamidation) of 250 μM
of the primary amine 5-biotin-pentylamine (5BP). For
deamidation analysis a direct comparison between the MALDI
spectra acquired before and after transglutaminase reaction
on the peptide mixture led to the identification of peptides
containing glutamine (Q) residues that were converted to
glutamic acid (E) residues by tTG-mediated deamidation.
Peaks originating from modified peptides showed a mass shift
of 1 Da for each modified Q residue. For analysis of
transamidation incorporation of 5BP was observed as a mass
increment of 311 Da in the mass spectra. MALDI-ToF only
shows whether transamidation has occurred or not, and does
not give any quantitative result. The reaction was performed
at 37 °C. Five μl aliquots were removed at given time-points
and the reaction stopped by adding iodoacetamide to a final

Figure 1. Potential tissue transglutaminase substrate consensus motif site on human PKCδ. Located along the regulatory domain of
PKCδ are the individual membrane binding domains, such as the C2-like and DAG/PMA binding motifs (C1a and C1b). Indicated on the
catalytic domain of the enzyme are the positions of the phosphorylatable serine/threonine residues such as the activation loop
domain (phosphorylatable amino acids are in yellow). Located C-terminal to the activation-loop threonine is a sequence (GQSP),
which potentially represents a tTG consensus substrate sequence (GQxP motif where x = any amino acid).
Please cite this article as: G. Byrne, et al., Protein kinase C delta is a substrate of tissue transglutaminase and a novel autoantigen in coeliac
disease, Clin. Immunol. (2013), http://dx.doi.org/10.1016/j.clim.2013.01.007
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after 8, 16, 45 and 96 min.
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with polyangiitis (9 male, 4 female; range 12–80; median 57).
Ethical approval for this study was obtained from the joint
ethics committee of St James's and Tallaght hospitals.

2.2. MALDI-ToF analysis
2.7. PKCδ ELISA assay
The samples were diluted in 0.1% trifluoroacetic acid and
spotted directly on a MALDI target plate (“dry-droplet”) 1:1
with 5 mg/ml α-cyano-4-hydroxycinnamic acid as matrix.
Each spectrum saved is the sum of approximately 1000 shots.

2.3. Polymerisation assays
One microgram of recombinant human PKCδ (Merck Biosciences) was incubated in the presence or absence of 1 μg
recombinant human tTG (Roboscreen) in a reaction buffer
containing 100 mM Tris, 10 mM CaCl2, 10 mM DTT (pH 8) for
30 min at 37 °C.

2.4. Western blotting
Samples were separated on a 12% SDS-PAGE gel, transferred
to a PVDF membrane and probed for polymerisation products
using a 1:1000 dilution of mouse anti-human tTG CUB7402
(Labvision) or a 1:1000 dilution of mouse anti-human PKCδ
(Santa Cruz). Bands were detected by the addition of rabbit
anti-mouse HRP (Dako) and developed with a solution
containing 12mls 100 mM Tris, 60 μl 250 mM luminol,
26.6 μl 90 mM p-coumaric acid and 3.8 μl 30% H2O2.

2.5. Hexapeptide substrate incorporation assays
Two N-terminally biotinylated hexapeptides, biotin-GQDPVR
(Q-donor) and biotin-GNDPVK (K-donor), were used as probes
to detect tTG-catalysed crosslinking. One microgram of
recombinant human tTG (Roboscreen), 1 μg recombinant
PKCδ (Calbiochem) and 2.5 μg of either lysine or glutamine
substrate biotinylated hexapeptide probe were incubated in a
reaction buffer containing 100 mM Tris, 10 mM CaCl2, 10 mM
DTT (pH 8) at 37 °C for 30 min (final volume 25 μl). In each
assay a tube containing tTG, glutamine substrate probe and
known tTG substrate N,N dimethylcasein (Sigma Aldrich) was
included as a positive control. Reaction volumes were
separated in a 12% SDS-PAGE gel and blotted onto a PVDF
membrane. After blocking for 1 h with 5% non-fat dried milk
with 0.1% Tween-20, blots were probed with Extravidin®
peroxidase (Sigma-Aldrich). Blots were developed for 3 min in
a solution containing 12mls 100 mM Tris, 60 μl 250 mM
luminol, 26.6 μl 90 mM p-coumaric acid and 3.8 μl 30% H2O2.

2.6. Serum samples
Serum samples were collected from 30 patients with coeliac
disease (11 male, 19 female; age 22–77, median 46). Diagnosis
was based upon a positive endomysial antibody test as well as
elevated anti-tTG antibody levels and positive duodenal
biopsy results. Sera from 15 healthy controls (2 male, 13
female; age 20–56; median 28) were also analysed. Disease
control samples included samples from 8 patients with
systemic lupus erythematosis (1 male, 7 female; age 4–41;
median 27) and 15 samples from patients with granulomatosis

ELISAs were performed by coating 96‐well Maxisorp® plates
(Nunc) with 1 μg per well of recombinant human PKCδ
(Sigma-Aldrich) overnight at 4 °C. Wells were blocked with 1%
HSA (Sigma-Aldrich) in PBS for 1 h and washed four times with
PBS plus 0.1% Tween between each step. Human sera were
diluted 1:20 with PBS plus 0.1% Tween followed by 1:1000
rabbit anti‐human IgA conjugated to HRP (Dako). All antibody
incubations were performed at room temperature for 1 h.
ELISAs were developed using 3,3′,5,5′‐tetramethylbenzidine
liquid substrate system (Sigma‐Aldrich) and were read at
450 nm in a spectrophotometer. A cut off for positivity was
established as the mean + 2 SD of the control population.

2.8. Statistical analysis
ELISA results from different sample groups were analysed
using the non parametric Mann–Whitney U test.

3. Results
3.1. A peptide sequence from PKCδ is a substrate for
deamidation by tTG
Analysis of the amino acid sequence of PKCδ identified a
glutamine-containing sequence (MLIGQSPFH) that, according
to the algorithm determined by Vader et al., represented a
potential glutamine substrate sequence for tTG (Fig. 1). The
motif QXP where X is any amino acid is reported to be a good
substrate for tTG-mediated deamidation [5]. In order to test
this hypothesis a peptide corresponding to the PKCδ sequence
was synthesised and tested for deamidation by tTG
using MALDI-ToF analysis. The known peptide substrates
ALPTAQVPTDP from rat heat shock protein 20 and
PFPQPQLPYPR from the DQ2-α-I epitope from α-gliadin were
used as positive controls (Q residues in bold are known targets
for deamidation by tTG). Deamidation can be calculated from
the acquired MALDI-ToF mass spectra by calculating the
centroid shift in the isotopic peak of the peptide. A complete
shift of 1 Da equals one complete deamidation.
Incubation of tTG with PKCδ peptide MLIGQSPFH resulted
in a centroid shift in the isotopic peak that was visible at the
45-minute time point indicating deamidation had taken
place. While deamidation occurred in the PKCδ peptide, it
was considerably slower than the control peptides, which
both demonstrated deamidation after 8 min (Figs. 2a & b).

3.2. A peptide sequence from PKCδ is a crosslinked
to 5BP in vitro
In order to determine whether the peptide MLIGQSPFH from
PKCδ could act as a glutamine substrate for tTG in a
transamidation reaction, the peptide was incubated in
reaction buffer with tTG and 5BP, a well-characterised
lysine substrate of tTG. Incorporation of 5BP into MLIGQSPFH

Please cite this article as: G. Byrne, et al., Protein kinase C delta is a substrate of tissue transglutaminase and a novel autoantigen in coeliac
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Figure 2. The peptide MLIGQSPFH derived from PKCδ is deamidated and transamidated by tTG. a: Deamidation of the glutamine
residue in the peptide can de calculated from the acquired MALDI-TOF mass spectra by calculating the centroid shift in the isotopic
peak of the peptide. A complete shift of 1 Da equals one complete deamidation. Deamidation of MLIGQSPFH is less than that of known
deamidation targets PFPQPQLPYPR from gliadin or ALPTAQVPTDP from rat small heat shock protein 20. b: Deamidation reactions
represented as deamidations per peptide over 96 min. c: Transamidation with 5BP is reflected by a mass increment of 311 Da in the
mass spectra.

results in a 311 Da increase in mass that can be detected by
MALDI-ToF. Analysis of the transamidation reaction demonstrated an increase in mass corresponding to 5BP indicating
that the PKCδ-derived peptide is a substrate for tTG-catalysed
transamidation (Fig. 2c).

3.3. Recombinant PKCδ is a glutamine substrate of tTG
The incorporation of biotinylated hexapeptide probes is an
established method for the investigation of potential substrates of tTG [20]. Incorporation of lysine-containing probe
(biotin-GNDPVK) indicates that a protein is a glutamine
substrate of tTG, while the incorporation of glutaminecontaining probe (biotin-GQDPVR) indicates that a protein is
a lysine substrate of tTG. In these experiments, the incorporation of the probes was investigated by using extravidin
peroxidase to detect biotinylated proteins in Western blots.
The known glutamine substrate N′N-dimethylcasein was used
as a positive control.
Blots showed the presence of a tTG-dependant band in
reactions containing the lysine substrate probe and PKCδ at

the apparent molecular weight of tTG (~ 80 kDa). This result
demonstrates that tTG can act as a lysine substrate for itself
(Fig. 3). In the same lane, a biotinylated protein band was
visible at high molecular weight, at the interface between
stacking and resolving gels. No band was apparent at the
molecular weight of recombinant PKCδ that was slightly
lower at 77.5 kDa suggesting that PKCδ does not behave as a
lysine substrate for tTG. In the reactions containing the
glutamine substrate probe, PKCδ and tTG, a biotinylated
band was visible at the molecular weight of PKCδ, indicating
that it behaves as a glutamine substrate for tTG. Once again,
a high molecular weight biotinylated band was apparent at
the interface between stacking and resolving gels.

3.4. tTG catalyses the formation of high molecular
weight PKCδ-tTG complexes
A reaction mixture containing PKCδ and tTG was incubated
at 37 °C for 30 min and then subjected to Western blotting
in order to characterise any resulting high molecular weight
complexes. Western blots with a monoclonal anti-PKCδ

Please cite this article as: G. Byrne, et al., Protein kinase C delta is a substrate of tissue transglutaminase and a novel autoantigen in coeliac
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Figure 3. Western blot demonstrating the incorporation of
hexapeptide substrate probes into PKCδ and tTG. Recombinant
tTG and PKCδ were incubated in a transglutaminase reaction
buffer with biotinylated hexapeptides that are established
glutamine and lysine substrates for tTG. Western blots were
probed with Extravidin® peroxidase in order to detect incorporated probes. In the absence of tTG (lanes 1 + 3) no probes are
incorporated into PKCδ. In lane 2 a band appears at the
molecular weight of tTG as well as a high molecular weight
band where the lysine substrate probe has been incorporated. In
lane 4 a band appears at the molecular weight of PKCδ as well as
a high molecular weight band where the glutamine substrate
probe has been incorporated. Lane 5 contains DMC, a known
glutamine substrate of tTG. The glutamine substrate probe has
been incorporated into DMC resulting in a band at 30 kDa.

antibody showed that incubation with tTG resulted in a
reduction of the PKCδ band intensity (Fig. 4a). A longer
exposure time revealed higher molecular weight bands at
~160 kDa and at the stacking/resolving gel interface (Fig. 4b).
Western blots of polymerisation reactions with a monoclonal
anti-tTG antibody demonstrated that incubation of tTG and
PKCδ resulted in high molecular weight bands of equal size to
those observed in the PKCδ blots suggesting that the high
molecular weight bands are tTG–PKCδ heterodimers (Fig. 4c).
A band at the molecular weight of PKCδ was also apparent
after the polymerisation reaction occurred. The reason for the

5

Figure 4. tTG catalyses the polymerisation of PKCδ. a: The
combination of PKCδ and tTG in a transglutaminase reaction buffer
results in the reduction of the PKCδ band at 80 kDa detected by
Western blotting with anti-human PKCδ. Lane 1: 1 μg of recombinant PKCδ. Lane 2: Mock polymerisation reaction — 1 μg of PKCδ in
reaction buffer with no tTG. Lane 3: The addition of tTG resulted in
the reduction of the PKCδ band. b: A longer exposure of lane 3 from
Fig. 3a reveals the presence of higher molecular weight bands at
~160 kDa and at the stacking/resolving gel interface. c: A
polymerisation reaction containing tTG and PKCδ results in the
production of high molecular weight bands that are recognised by a
monoclonal anti-tTG antibody in a Western blot. A band also
becomes apparent at the molecular weight of PKCδ.

appearance of this band is unknown but the deamidation of
PKCδ by tTG could potentially result in the formation of a
neoepitope that interacts with the anti-tTG monoclonal
antibody.

3.5. Elevated levels of IgA anti-PKCδ antibodies are
detectable in sera from patients with coeliac disease
but not in patients with other autoimmune conditions
ELISAs were performed with sera from patients with coeliac
disease, granulomatosis with polyangiitis, systemic lupus
erythematosis and control samples using recombinant PKCδ
as antigen. A highly significant (p b 0.0001) increase in IgA
anti-PKCδ was observed in the coeliac sera, but not in
control sera or either autoimmune disease control (Fig. 5).
There was no correlation between levels of anti-PKCδ
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Figure 5. Patients with coeliac disease produce elevated levels
of IgA anti-PKCδ. Sera from patients with coeliac disease contain
elevated levels of anti-PKCδ autoantibodies (pb 0.0001). Cut-off
for positivity is represented by a dotted line and was calculated
based on the mean + 2SD of the results from the control samples.
Disease controls were systemic lupus erythematosis (SLE) and
granulomatosis with polyangiitis (GPA).

antibodies and anti-tTG antibodies (R 2 = 0.09, data not
shown). Of the coeliac disease patient sera, 17 of 30 (57%)
demonstrated elevated anti-PKCδ antibodies. Those samples
with the highest levels of anti-PKCδ antibodies (OD N 1.4)
were reported as having an atypical EMA pattern that is
associated with the production of other autoantibodies.

4. Discussion
In these experiments we have demonstrated that PKCδ is a
glutamine substrate for tTG-mediated deamidation and
transamidation. Amino acid sequence analysis identified a
tTG substrate motif (QXP) in the catalytic domain of
PKCδ at position 545 and a peptide corresponding to the
541
MLIGQSPFH 549 sequence of PKCδ was shown to be
deamidated and transamidated by tTG in MALDI-ToF
experiments. Biotinylated substrate probe incorporation
assays and polymerisation assays were used to show that
this enzyme-substrate interaction occurs in the full-length
proteins and that tTG–PKCδ heterodimers are formed by
the interaction. Finally, we have shown that a population
of patients with coeliac disease has significantly elevated
levels of IgA anti-PKCδ antibodies in their serum (p b 0.001)
and that these autoantibodies are not elevated in patients
with systemic lupus erythematosis or granulomatosis with
polyangiitis.
tTG is a multifunctional enzyme which displays crosslinking,
deamidation, ATPase and protein disulphide isomerase activity
[21,22]. The enzyme has been implicated in cellular processes
as diverse as apoptosis [23], tissue repair [24], G-protein

signalling [25] and cytokine activation [26,27]. The enzyme
plays a role in the modification of gluten peptides in coeliac
disease and, through this interaction, becomes the target of an
IgA autoantibody response. The widely held belief is that
tTG-catalysed gliadin-tTG heterodimers act as a hapten-like
complexes which drive the production of anti-tTG antibodies
facilitated by gliadin-specific T-cell help [28]. While tTG is the
primary autoantigen in coeliac disease, some patients have
been shown to produce elevated levels of antibodies against
other self proteins including actin, desmin, reticulin, liver,
brain and parietal cell antigens [29]. tTG-mediated posttranslational modification of proteins by deamidation or
transamidation is a possible mechanism for neoepitope generation and the development of autoimmunity. It is noteworthy
that autoantigens (including actin, myosin and Histone 2B) from
a variety of autoimmune diseases are substrates for tTG [30]. It
is therefore conceivable that tTG-substrate interactions could
result in epitope spreading to other autoantigens.
A number of proteins that are involved in the apoptotic
process have been found to be autoantigens in disease states.
The effective clearance of apoptotic cells is essential in the
maintenance of tolerance and dysregulated phagocytosis of
apoptotic cells has been implicated in the pathogenesis of SLE
[31]. Significantly elevated levels of apoptosis have been
observed in epithelial cells of the coeliac disease small intestine
[32]. The main mechanism responsible for this phenomenon
appears to be pro-inflammatory cytokine-induced increases in
FAS/FASL expression [33]. PKCδ and tTG have both been
described as having integral roles in the control of apoptosis
[23,34]. Activation of tTG during apoptosis could result in
significant modification of the antigenic profile of dying cells.
Furthermore, crosslinking of proteins found in apoptotic blebs
could increase the half-life of these proteins, thus increasing
the exposure of these proteins to the immune system. It has
been demonstrated that the induction of apoptosis in colon
cancer cell lines is associated with shuttling of PKCδ to the cell
membrane potentially making it available for tTG interaction
and exposure to the immune system [35].
The production of anti-actin responses in coeliac disease
has been associated with the atypical EMA pattern and more
severe disease [11]. It is worth noting that in this study, PKCδ
autoantibody levels tended to be higher in those patients
that had an atypical EMA pattern (data not shown). Why
some patients tend to produce antibody responses against
other self-antigens is unknown but we propose a model
whereby increased apoptosis in the coeliac small intestine
results in the exposure of intracellular antigens on apoptotic
cells which become available for tTG-mediated modification. This results in a longer protein half life or neoepitope
formation, which culminates in autoantibody formation.
Whether these autoantibodies play a role in coeliac disease
pathogenesis is unknown but, given that PKCδ is normally
intracellular, they are unlikely to interact with their target
molecule except in the context of apoptosis or necrosis.
PKCδ is a signalling molecule which plays roles in diverse
cellular pathways including cell growth, proliferation,
differentiation and death [19]. In pancreatic cells, it has
been demonstrated that PKCδ regulates the expression of
tTG and that inhibition or silencing of PKCδ results in
decreased tTG expression and a concomitant increase in
autophagy in these cells [36]. Consistent with the finding
that PKCδ regulates tTG expression, is the fact that the
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phenotype of the tTG knockout mouse [37] and the PKCδ
knockout mouse [38] is remarkably similar. Interestingly,
both tTG −/− and PKCδ −/− mice contain circulating autoantibodies and display immune complex glomerulonephritis and
splenomegaly.
The discovery that PKCδ is a substrate for tTG cross-linking
suggests the possibility that tTG-mediated cross-linking could
act as a regulator of PKCδ activity in a negative feedback loop.
The majority of intracellular tTG is assumed inactive due to a
scarcity of Ca 2+ but recent evidence has confirmed that during
the early stages of apoptosis perinuclear tTG assumes its
active conformation and is capable of crosslinking proteins
[39].
In summary we have demonstrated that PKCδ is a novel
glutamine substrate for the enzyme tTG and that the tTG–PKCδ
interaction results in heterodimer formation. Furthermore we
have shown that a subset of patients with coeliac disease
produce autoantibodies that bind PKCδ. The origin and
significance of this response demand further investigation.
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